Clinical trials: Chimeric Antigen Receptor T-cell Therapy
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study
This is a Phase I/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic…
- Trial name
- CARLLA-B1 (NCT07890025)
- Testing
- MB-CART19.1
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Non-hodgkin Lymphoma
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
This is a multi-center, open-label, single-arm, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (r/r B-NHL).
- Trial name
- NCT06005649
- Testing
- HY004
- Sponsor
- Juventas Cell Therapy Ltd.
Multiple Myeloma
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
- Trial name
- NCT07073547
- Testing
- AZD0120
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with B cell lymphomas or leukemias that involves taking white blood cells from the patient, growing them…
- Conditions
- Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, Mantle Cell
- Trial name
- NCT00924326
- Testing
- Fludarabine, Cyclophosphamide, Anti-cluster of differentiation 19 (CD19)-CAR PBL
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
This phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not…
- Conditions
- Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm
- Trial name
- NCT04510051
- Testing
- Cyclophosphamide, Fludarabine, IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Malignant Neoplasms of Digestive Organs
CART Therapy in Digestive System Tumors
Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric…
- Trial name
- NCT04780529
- Testing
- gucy2c cart cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Innovative Cellular Therapeutics Co., Ltd.
B-cell Malignancy, B-cell Lymphoma
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
This is a single center, single arm, open-label phase 1 study to determine the safety and efficacy of autologous T cells expressing CD19 chimeric antigen receptors in adults with CD19+ B cell malignancies.
- Conditions
- B-cell Malignancy, B-cell Lymphoma, B-Cell Acute Lymphoblastic Leukaemia
- Trial name
- NCT03559439
- Testing
- CD19 CAR T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Tong Ren Hospital
Colorectal Cancer, Esophageal Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer
- Trial name
- NCT05415475
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Newly Diagnosed Multiple Myeloma (NDMM)
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete…
- Trial name
- DURGA-6 (NCT07735637)
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Multiple Myeloma (MM), CAR T Cells
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
This study investigates whether raising blood levels of beta-hydroxybutyrate (BHB) - a natural molecule produced by the body during fasting or a low-carbohydrate diet - is safe and feasible and can improve the effectiveness of…
- Conditions
- Multiple Myeloma (MM), CAR T Cells, Bispecific Antibodies
- Trial name
- BEAM-MM (NCT07564219)
- Testing
- Ketogenic diet, Ketogenic Drinks
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Leukemia, B-cell
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19/CD22 positive Relapsed or…
- Trial name
- NCT03614858
- Testing
- CART-19/22
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Multiple Myeloma, Newly Diagnosed
CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?
This is a prospective study comparing anti-BCMA CAR-T to autologous hematopoietic stem cell transplantation alone in the treatment of newly diagnosed multiple myeloma patients.
- Trial name
- ASCTvsCAR-T (NCT07070934)
- Testing
- CAR-T, ASCT
- Volunteers
- 60 people
- Sponsor
- Xuzhou Medical University
B-ALL
Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This study is an open, dose-escalating clinical study, taking patients with relapsed or refractory acute lymphoblastic leukemia as the test subjects, including mouse-derived CAR-T treatment failure or relapse, or for any reason…
- Trial name
- NCT04792593
- Testing
- Senl-h19 CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory…
- Conditions
- Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL
- Trial name
- ACIT001/EXC002 (NCT03938987)
- Testing
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
- Where
- 6 sites in Canada
- Volunteers
- 63 people
- Sponsor
- University of Alberta
CS1+ or BCMA+ Multiple Myeloma
T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of the bispecific CAR T cells targeting CS1 and BCMA in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT04662099
- Testing
- Conditioning chemotherapy followed by CAR T cell infusion
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Large B-cell Lymphoma, B-cell Lymphoma
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
To evaluate the efficacy of the combination of magrolimab, rituximab, and radiation as bridging therapy in patients with relapsed or refractory LBCL who receive CAR T-Cell Therapy (CART).
- Trial name
- NCT05929716
- Testing
- Magrolimab, Rituximab, CAR T leukapheresis
- Sponsor
- M.D. Anderson Cancer Center
Neoplasm, Stomach, Metastases, Neoplasm
Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
To investigate the safety and efficacy of intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.
- Conditions
- Neoplasm, Stomach, Metastases, Neoplasm, Neoplasm Seeding
- Trial name
- NCT03563326
- Testing
- CAR-T cells targeting EpCAM, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jian-Kun Hu
Multiple Myeloma
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a…
- Trial name
- NCT05393804
- Testing
- Ide-cel (bb2121)
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Leukemia, Acute Leukemia Refractory
Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
CAR-T therapy has evolved as a pivotal treatment for relapsed/refractory (R/R) leukemia, demonstrating improved remission rates and manageable adverse events.
- Conditions
- Acute Leukemia, Acute Leukemia Refractory, Acute Myeloid Leukemia (AML), ALL (Acute B-Lymphoblastic Leukemia)
- Trial name
- NCT07087847
- Testing
- TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Light Chain Amyloidosis
FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
This study is a single-center exploratory clinical trial. It is estimated that 6-12 subjects will be enrolled. The "BOIN" dose escalation design is adopted.
- Trial name
- NCT05978661
- Testing
- FKC288
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanjing University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.